Boston Scientific accounts are for healthcare professionals only.
Intera 3000™ Hepatic Artery Infusion Pump
Reimbursement
Configure or select a product to continue to order
- Overview
- Technical and ordering information
- Resources
A powerful liver-directed treatment for patients with CRLM and iCCA
HAI therapy exposes tumors in the liver to up to 400x greater drug concentration than systemic infusion while minimizing systemic exposure.1
The HAI pump continuously perfuses the entire liver, allowing patients to maintain their quality of life.2
1. Ensminger WD, Gyves JW. Semin Oncol. 1983;10(2):176-8
2. Ensminger WD, et al. Cancer Res. 1978;38(11 Pt 1):3784-92.
Ordering information
Product Number | Material Description | Unit of Measure |
AP-03000H | Hepatic Artery Infusion Pump | Each |
AP-07014US | HAI Pump Refill Kit | Each |
AP-07004 | HAI Pump Operating Room Prep Kit | Each |
AP-04030 | Non-Coring Refill Needle, 2 IN, 15PK | Box - 15 |
AP-04013-5 | Special Bolus Needle, 1 3/8 IN, 5PK | Box - 5 |
AP-04032-5 | Special Bolus Needle, 2 IN, 5PK | Box - 5 |
IP-37957 | HAI Tapered Catheter | Each |
81643-9270-1 | FLOXURIDINE FOR INJECTION, USP | Each |
View HAI instructions for use and other resources. HAI Resource Portal
Clinical summary series:
HAI Therapy for CRLM and iCCA
Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
Cowzer D et al. 2024
Taken together, results of the prospective phase II study and retrospective analysis of routine clinical care underscore the ability of HAI to achieve durable long-term disease control and prolonged survival in patients with advanced, unresectable iCCA.
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma—PUMP-2 trial
Franssen S, et al. 2025
A multicenter trial from the Netherlands—the PUMP-2 study—has shown remarkable survival benefits for patients with unresectable intrahepatic cholangiocarcinoma (iCCA) confined to the liver.
Combined hepatic arterial infusion pump and systemic chemotherapy in the modern era for chemotherapy-naïve patients with unresectable colorectal liver metastases
Verheij FS, et. al., 2023
This single-center retrospective cohort study showed that chemotherapy-naïve patients with unresectable colorectal liver metastases (CRLM) who received HAI + systemic chemotherapy had a high rate of conversion to resection or complete response, which was associated with prolonged survival.
Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
Holster JJ, et. al., 2022
This systematic review of 9 publications demonstrated HAI was associated with substantial improvement in survival for unresectable intrahepatic cholangiocarcinoma (iCCA) patients.
